Nintedanib Centrafarm (Nintedanib)

Nintedanib inhibits the kinase activity of VEGFR, FGFR and PDGFR receptors. By blocking these signals it reduces fibroblast proliferation, extracellular matrix formation and new blood‑vessel growth. This dual antifibrotic and anti‑angiogenic effect underlies its benefit in lung fibrosis and selected cancers.

The exact dose and dosing schedule are determined by the prescribing clinician based on the patient’s specific indication, disease severity, renal and hepatic function, and any concomitant medications. Dosing recommendations are provided in the product’s prescribing information and should be individualized for each patient.

Nintedanib is not recommended for use during pregnancy or while breastfeeding unless the potential benefit justifies the potential risk to the fetus or infant. Women of child‑bearing potential should use effective contraception during treatment and discuss any pregnancy plans with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Nintedanib Centrafarm. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and the necessary import documentation.

Compared with pirfenidone, another approved antifibrotic, Nintedanib targets a broader range of receptor tyrosine kinases (VEGFR, FGFR, PDGFR) and may be chosen for patients who cannot tolerate pirfenidone’s gastrointestinal profile. Both drugs slow lung‑function decline in idiopathic pulmonary fibrosis, but the choice depends on individual tolerability, comorbidities and physician judgment.

Nintedanib Centrafarm should be stored below 25 °C (77 °F) in its original packaging, protected from moisture and direct light. Do not store in a bathroom or near a heat source. Keep the product out of reach of children and check the expiry date before use.

The medication is taken orally, usually with food to lessen gastrointestinal discomfort. Capsules (or tablets, depending on the marketed form) are swallowed whole with a glass of water. Patients should follow the prescribing clinician’s instructions regarding timing and any dose adjustments.

The most serious adverse events include severe liver injury (elevated ALT/AST), major bleeding episodes, and cardiovascular events such as arterial thromboembolism or myocardial infarction. Patients should report signs of jaundice, unusual bruising, chest pain, or sudden shortness of breath to their healthcare provider promptly.

Nintedanib is contraindicated in patients with known hypersensitivity to the active substance or any excipients, in those with active, clinically significant bleeding, and in individuals with severe hepatic impairment. Caution is also advised for patients on strong CYP3A4 inhibitors or anticoagulants, and it should be avoided in pregnancy unless absolutely necessary.